公开(公告)号：US20240091202A1

公开(公告)日：2024-03-21

申请号：US18280329

申请日：2022-03-04

Applicant: Universität Basel

Inventor： Christoph HESS ,  Bojana MÜLLER-DUROVIC ,  Glenn BANTUG

IPC: A61K31/4245 ,  A61K31/47 ,  A61P31/22 ,  C07K16/40 ,  C12N15/113 ,  C12Q1/6874 ,  C12Q1/70

CPC classification number: A61K31/4245 ,  A61K31/47 ,  A61P31/22 ,  C07K16/40 ,  C12N15/1137 ,  C12Q1/6874 ,  C12Q1/701 ,  C12N2310/14 ,  C12N2320/31 ,  C12Q2600/106

Abstract: The invention relates to the treatment and prevention of diseases and conditions associated with EBV infection. In particular, the invention is directed to the use of an IDO1 inhibitor for the treatment and prevention of diseases and conditions associated with EBV infection. The invention also relates to methods for predicting the risk of developing a disease or condition associated with EBV infection.

公开(公告)号：US20240010726A1

公开(公告)日：2024-01-11

申请号：US18021323

申请日：2021-08-17

Applicant: Universität Basel

Inventor： Jonas LÖTSCHER ,  Christoph HESS

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00

CPC classification number: C07K16/2818 ,  A61P35/00 ,  A61K9/0019

Abstract: The present invention relates to an LFA-1 signalling mediator with moderate LFA-1 stabilization properties for use in cancer immunotherapy or a composition for use in cancer immunotherapy comprising an immune system modulator, wherein the immune system modulator enhances the immune response against cancer, and an LFA-1 signalling mediator with moderate LFA-1 stabilization properties wherein the LFA-1 signalling mediator selectively and significantly enhances the anti-cancer immune response. The composition may comprise a carrier for target delivery of the composition.

公开(公告)号：US20220306989A1

公开(公告)日：2022-09-29

申请号：US17635534

申请日：2020-08-19

Applicant: Universität Basel

Inventor： Jasmin GRÄHLERT ,  Christoph HESS

IPC: C12N5/0783 ,  C07K14/725 ,  C07K16/30 ,  C12N15/86 ,  A61P35/00

Abstract: The present invention is in the field of cell therapy and provides compositions and methods for treating cancer and/or viral infections in patients. The invention provides lymphocytes comprising a synthetic polynucleotide encoding at least one iron regulatory protein and, optionally, a chimeric antigen receptor. The invention further provides methods for producing these lymphocytes and administering them to patients.